DETAILED ACTION
Status of Application
The Examiner acknowledges receipt of the amendments filed on 2/2/2025 wherein claim 1 has been amended and claims 2 and 3 have been cancelled.
Claims 1 and 4-13 are presented for examination on the merits. The following rejections are made.
Response to Applicants’ Arguments
Applicant’s amendments filed 11/4/2025 overcome the rejection of claims 1, 2, 7 and 10 made by the Examiner under 35 USC 102(a)(1) over Zhao et al. (JACS, 2016, 138, 16645-16654). This rejection is withdrawn.
Applicant’s amendments filed 11/4/2025 overcome the rejection of claims 1, 7, 8 and 10 made by the Examiner under 35 USC 102(a)(1) over Bouvrette et al. (US 2005/0153071). This rejection is withdrawn.
Applicant’s amendments filed 11/4/2025 overcome the rejection of claims 1-3 and 7-10 made by the Examiner under 35 USC 103 over Zhao et al. (JACS, 2016, 138, 16645-16654), evidenced by gamma-cyclodextrin (Pubmed). This rejection is withdrawn.
Applicant’s amendments filed 11/4/2025 overcome the rejection of claims 4, 6 and 12 made by the Examiner under 35 USC 103 over Zhao et al. (JACS, 2016, 138, 16645-16654), evidenced by gamma-cyclodextrin (Pubmed), further in view of Anderson et al. (J Nanopart Res, 2011, 13, 2843-2851). This rejection is withdrawn.
Applicant’s amendments filed 11/4/2025 overcome the rejection of claims 5 and 11 made by the Examiner under 35 USC 103 over Zhao et al. (JACS, 2016, 138, 16645-16654), evidenced by gamma-cyclodextrin (Pubmed), further in view of Hammami et al. (J King Saud Uni, 33, 2021, 1-10). This rejection is withdrawn.
Applicant’s amendments filed 11/4/2025 overcome the rejection of claims 8 and 13 made by the Examiner under 35 USC 103 over Zhao et al. (JACS, 2016, 138, 16645-16654), evidenced by gamma-cyclodextrin (Pubmed), further in view of Bouvrette et al. (US 2005/0153071). This rejection is withdrawn.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claims 1 and 4-13 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
Claim 1 recites, “…the amount of the CD-MOF material is based on an amount of the γ-CD; a molar ratio of the γ-CD to the chloroauric acid is in a range of 5:1 To 7.5:1; and a ratio of an amount of substance of the chloroauric acid to a volume of the solvent is in a range of 1.25 mmol: 1L to 1.5 mmol:1.” The limitation to “a ratio of an amount of substance of the chloroauric acid…” is indefinite because it is unclear if the ratio is to “a substance” or “the chloroauric acid”. Clarification as to what the ratio is for is requested.
Claims 4-13 are rejected for depending from an indefinite claim.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/KYLE A PURDY/ Primary Examiner, Art Unit 1611